NAYA Biosciences Emerges from INVO Merger with Expanded Focus

3 min read | October 14, 2024 03:15 PM PDT | By Team Kalkine Media

Google News:

NAYA Biosciences Emerges from INVO Merger with Expanded Focus — Image source: Shutterstock

Recent News

Is Pitney Bowes Still Hiding Value After Its Rally?

What’s Driving Unity Bancorp Climb To New Highs?

Why United Parcel Service Is Back on The Market Radar?

Why Is Halliburton Facing Fresh Market Pressure?

Make Kalkine Media
My Trusted Source

Highlights

INVO Bioscience has successfully merged with NAYA Biosciences, forming a new entity that combines INVO's fertility business with NAYA's advancements in oncology and autoimmune disease therapies, operating under the name NAYA Biosciences.

The newly merged company will focus on maintaining a profitable fertility division while expanding into innovative therapeutic developments, including cancer treatments, through its bispecific antibody programs.

With leadership roles clearly defined, the combined company aims to leverage its revenue-generating fertility segment to support the advancement of its oncology and autoimmune treatment pipeline, positioning itself as a multi-faceted healthcare provider.

INVO Bioscience, a prominent player in the Healthcare sector, has completed its merger with NAYA Biosciences, creating a new entity now known as NAYA Biosciences. The company, which will trade under the NASDAQ ticker NAYA, brings together INVO's well-established fertility business with NAYA's innovative therapeutic developments in oncology and autoimmune diseases. This merger represents a strategic move to broaden the company’s focus while building on existing revenue streams from its fertility division.

Combining Fertility and Therapeutic Innovation

The merger of INVO Bioscience and NAYA Biosciences (NASDAQ:NAVA) marks a significant step forward in the biotechnology sector. INVO’s fertility business has been a cornerstone of the company’s operations, providing a steady source of revenue. With the merger, NAYA Biosciences expands its portfolio to include groundbreaking therapeutic programs targeting oncology and autoimmune diseases. Notable among these advancements are the GPC3-targeting FLEX-NK bispecific antibody, which is entering clinical trials for hepatocellular carcinoma, and a CD38-targeting FLEX-NK bispecific antibody for multiple myeloma and autoimmune conditions.

This combined approach allows the new NAYA Biosciences to leverage its fertility business to fuel research and development in areas of high unmet medical need, positioning the company to play a vital role in both reproductive health and advanced medical therapies.

Strategic Leadership for Future Growth

The leadership team at NAYA Biosciences is positioned to guide the company’s ambitious goals. Steve Shum, formerly of INVO Bioscience, will take on the role of CEO, while Dr. Daniel Teper has been appointed President and CEO of the NAYA Therapeutics subsidiary. This leadership structure ensures that both the fertility and therapeutic divisions receive dedicated oversight, with an emphasis on driving growth in each area.

Expanding Horizons in Biotechnology

With this merger, NAYA Biosciences is poised to make significant strides in the biotechnology industry. By combining INVO’s fertility business, which continues to generate revenue, with NAYA’s focus on developing therapies for complex diseases, the company is positioned as a diversified healthcare provider. This strategic merger not only enhances its market presence but also enables the company to pursue new opportunities in cutting-edge medical research.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.